Multiple Myeloma Education

10/19/2022

NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

https://www.themyelomaclinicaltrials.com/single-post/isb1442-ichnos

https://www.themyelomaclinicaltrials.com/rrmm

10/19/2022

Recruiting: NCT05027594: Phase 1: Study of NMS-03597812, a PERK Inhibitor in Adult Pts With Relapsed or Refractory Myeloma
https://www.themyelomaclinicaltrials.com/single-post/nms-03597812

https://www.themyelomaclinicaltrials.com/rrmm

09/29/2022

NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma just published in NEJM

https://tinyurl.com/3f5j5syf

09/13/2022

NCT04566328: Phase 3 - Testing the Use of Combination Therapy in NDMM, the EQUATE Trial - EAA181 https://www.themyelomaclinicaltrials.com/single-post/equate

06/13/2022

Data Driven Individualized Treatments for every patient - Pathway towards cure

IMWG Conference Series, “Making Sense of Treatment” on June 16. Leading myeloma experts will discuss the latest drug therapy news from the American Society of Clinical Oncology (ASCO) conference, IMF IMWG Summit, and the European Hematology Association (EHA) Annual Conference. https://bit.ly/3tyk0yh

05/11/2022

You just can't beat the person who won't give up -Babe Ruth

Multiple Myeloma Clinical Trials info and Multiple Myeloma Education Platform for Patients and Families.

05/03/2022

04/27/2022

This video comes from a lady who wants to know about mass spectrometry. She's heard this phrase and she wants to know: "Is this a test that I should be aware of?"
https://www.myeloma.org/blog/future-myeloma-care

04/26/2022

Revlimid (lenalidomide) is an immunomodulatory agent for treatment of Multiple Myeloma. Here are some of the common things to watch out for while receiving this treatment. Learn more about it’s possible side effects and management in drug section of the website by visiting www.mmeducation.org

Multiple Myeloma Clinical Trials info and Multiple Myeloma Education Platform for Patients and Families.

04/26/2022

Revlimid (lenalidomide) is an immunomodulatory agent for treatment of Multiple Myeloma. Here are some of the common things to watch out for while receiving this treatment. Learn more about it’s possible side effects and management in drug section of the website by visiting www.mmeducation.org